Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Institutes for BioMedical Research Inc.

Latest From Novartis Institutes for BioMedical Research Inc.

Amgen Doubles Down On AI, Genomic Investments In R&D

David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.

Artificial Intelligence Strategy

Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D

Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.

Leadership Companies

Who Wants To Live Forever? Forging A Regulatory Pathway For Longevity Drugs

Despite the growing interest, both in and outside of the biotech space, in the so-called ‘longevity’ industry, no regulatory pathway exists to market a drug with a purely geroprotective indication.

Innovation Regulation

J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief

The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.

Executive Changes Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals